StockNews.AI
NTRA
StockNews.AI
175 days

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

1. Natera’s Signatera test earns CMS coverage for NSCLC surveillance. 2. Expanded coverage could enhance revenue and long-term market positioning.

2m saved
Insight
Article

FAQ

Why Bullish?

The CMS decision increases patient access and testing adoption, similar to past regulatory wins that uplifted biotech stocks. Historical instances like FDA approvals for companion diagnostics spurred revenue growth.

How important is it?

Gaining CMS coverage marks a pivotal regulatory milestone that can accelerate market penetration and boost investor confidence, thus directly impacting Natera’s stock performance.

Why Long Term?

Securing CMS coverage likely drives sustained adoption in NSCLC surveillance, creating ongoing revenue streams and competitive advantages over time.

Related Companies

ILMNEXASGH
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program (MolDX) for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients with stage I-III NSCLC with resectable or unresectable disease in the surveillance setting. It expands upon preexistin.

Related News